ModifiedUnitedHealthcarePolicy CS064ID.B

Intensity-Modulated Radiation Therapy (for Idaho Only)

Policy governing coverage and medical necessity of IMRT for specified indications in the state of Idaho, including Idaho Medicaid Plus plans; describes proven, investigational, and exception criteria and coding guidance.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for Idaho Only)

Policy CodePolicy CS064ID.B

Change TypeCriteria revisionadded indications and documentation requirements

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionProvide medical records that document the clinical indication, planning rationale, and that the member meets criteria for coverage when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

Removed notation indicating this policy applies to persons 19 years of age and older; IMRT is covered without further review for persons 18 years and younger.

Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary; added 'vulvar cancer' and replaced 'anal cancer' with 'anus /anal canal cancer'.

Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and applicable laws.

Added explicit Medical Records Documentation requirements that medical records must support medical necessity and may be requested.

Updated definition of 'Definitive Therapy' and supporting information sections (Description of Services, Clinical Evidence, References).

05/01/2026Effective date

Idaho onlyApplies to

Enumerated list

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

10HA-WBRT fraction limit

CS064ID.AArchived version

Coverage and Medical Necessity Criteria

Proven/Medically Necessary Indications

IMRT is proven and medically necessary for definitive therapy of the following primary sites or situations when ALL listed conditions for each indication are met as appropriate:

Proven Indications list: IMRT for definitive therapy of: anus/anal canal; breast cancer when left-sided internal mammary nodes are treated OR accelerated partial breast irradiation (APBI) up to 5 fractions; central nervous system (CNS) tumors (primary or benign) including brain, brainstem, and spinal cord; cervical cancer; endometrial cancer; esophageal cancer; head and neck cancers (including lymphoma and solitary plasmacytomas) when treatment includes pharynx (nasopharynx, oropharynx, hypopharynx), larynx (stage III/IV glottic), salivary glands, oral cavity (including tongue), nasal cavity, paranasal sinuses; mediastinal tumors (e.g., lymphomas, thymomas) including tracheal cancer; non-small cell lung cancer stage III undergoing chemoradiation; pancreatic cancer; prostate cancer; vulvar cancer; compensator-based beam modulation when performed in combination with an IMRT indication listed above as proven; hippocampal-avoidance whole brain radiation therapy (HA-WBRT) up to 10 fractions when all HA-WBRT-specific criteria are met.

Each listed site constitutes an acceptable proven indication per policy.

Case-by-Case Exceptions

Exception/Case-by-Case Coverage Conditions (when at least one condition is present):

Exception criteria: (1) Use of a clinically appropriate radiation dose delivered by a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity, as demonstrated by a comparison of IMRT and non-IMRT treatment plans (e.g., 3D-CRT) following RTOG or QUANTEC guidance; OR (2) The same or an immediately adjacent area has been previously irradiated and sculpting is required to avoid exceeding cumulative tolerance doses of nearby normal tissue.

Requests for IMRT not listed as proven may be approved if plan comparison or prior irradiation justification is provided.

Unproven / Not Medically Necessary

Not medically necessary / investigational:

Not medically necessary: IMRT used in conjunction with proton beam radiation therapy is unproven and not medically necessary due to insufficient evidence of efficacy.

Policy explicitly lists IMRT combined with proton therapy as unproven.

HA-WBRT Coverage Criteria

Hippocampal-avoidance whole brain RT specific criteria:

HA-WBRT criteria: HA-WBRT delivered with IMRT up to 10 fractions for brain metastases when ALL of the following are met: (1) planned whole-brain radiotherapy for brain metastases; (2) no metastases within the hippocampal-avoidance region (approximately within 5 mm of the hippocampus) and absence of leptomeningeal disease; (3) performance status ECOG ≤ 2 or Karnofsky performance status (KPS) ≥ 70; (4) estimated prognosis/life expectancy of approximately ≥ 4 months; and (5) concurrent use of memantine is planned per guideline recommendations.10 fractions

All listed conditions must be met for HA-WBRT coverage.

Guideline-supported use

Guideline-backed coverage stance where present:

Guideline preference for IMRT: Professional society guidelines (e.g., ASTRO, NCCN, ACR, ESMO/ESGO/ESTRO/ESP) state that IMRT/VMAT is preferred for specific tumor sites to reduce acute and late toxicity while maintaining local control, particularly when tumors are adjacent to critical organs-at-risk (OARs).

When claiming guideline-based preference, document target volumes, OAR constraints, and planning rationale.

Breast cancer

Clinical trial evidence for breast cancer applications:

APBI-IMRT for selected early breast cancer: Accelerated partial-breast irradiation (APBI) using IMRT (30 Gy in five fractions as in the APBI-IMRT Florence trial) produced low 10-year ipsilateral breast tumor recurrence and similar overall survival compared with whole-breast irradiation, with significantly less acute and late toxicity and improved cosmesis and HRQOL in selected low-risk patients.5 fractions

Patient selection should mirror trial low-recurrence-risk characteristics.

IMRT (including DIBH) for left-sided disease: IMRT with deep inspiration breath hold (DIBH) reduces cardiac and pulmonary dose when treating left-sided breast cancer and is useful when internal mammary nodes are targeted.

Use when left-sided internal mammary nodal irradiation is indicated.

3D-IMRT vs 2D RT: 3D-IMRT reduced late radiation adverse events and changes in breast appearance compared with historic 2D techniques in higher-risk breast anatomy, supporting use of conformal techniques to reduce normal tissue effects.

Central nervous system (CNS) tumors

CNS tumor evidence and recommendations:

IMRT for IDH-mutant grade 3 gliomas and large-volume disease: Prospective cohort data demonstrate significant volumetric tumor response, long-term PFS and OS, and acceptable late toxicity for large-volume IDH‑mutant grade 3 gliomas treated with IMRT with integrated boost; evidence is limited by single-center designs.

When IMRT unavailable, guidelines recommend 3D-CRT as an alternative.

IMRT benefits for low-grade gliomas: Randomized trial data suggest improved cognitive and QOL outcomes with conformal IMRT relative to 3D-CRT in some studies of low-grade gliomas, though OS differences are not established.

Study sizes and generalizability are limited.

ASTRO/NCCN stance for CNS: ASTRO strongly recommends IMRT/VMAT to reduce acute and late toxicity for WHO grade 2 and grade 3 diffuse gliomas; NCCN supports conformal techniques including IMRT for multiple CNS tumor types.

Document indication and consider 3D-CRT only when IMRT/VMAT is unavailable.

Cervical cancer

Cervical cancer evidence:

IMRT vs 3D-CRT for cervical cancer: Randomized and observational studies show equivalent survival outcomes with IMRT compared with 3D-CRT but with significantly lower acute and late GI/GU toxicities (including reduced bowel obstruction and chronic GU toxicity); ASTRO and NCCN recommend IMRT for postoperative and definitive pelvic RT to decrease toxicity.

IMRT should not routinely replace brachytherapy for central intact cervix disease.

Anal cancer

Anal cancer and professional guidance:

Anal cancer IMRT outcomes: Definitive photon IMRT with concurrent chemotherapy (DP-IMRT with 5FU/MMC) demonstrates long-term efficacy similar to conventional RT with decreased grade ≥3 late effects in cohort studies; evidence is limited by small study sizes.

No isolated nodal failures in elective nodal volumes reported in cited series.

Society guidance for anal cancer: ACR, ESMO, and NCCN endorse IMRT/VMAT for anal carcinoma to spare OARs and reduce toxicity and generally prefer IMRT over 3D‑CRT with strict OAR dose constraints and support of simultaneous integrated boost techniques.

Document OAR constraints and planning rationale when requesting IMRT.

Guideline-concordant coverage criteria

Coverage aligned with professional guidelines:

Guideline-preferred uses: IMRT is recommended or preferred by major guidelines for postoperative pelvic RT (cervical and endometrial cancer) and for definitive pelvic RT to minimize acute and chronic GI and hematologic toxicities; IMRT or proton therapy may be used in esophageal cancer when OAR dose reduction is required.

Sources include ASTRO, ACR, NCCN, ESGO/ESTRO/ESP.

Image-guidance: Routine use of IGRT (orthogonal or volumetric imaging) is essential when delivering IMRT to ensure target coverage and OAR sparing per guideline recommendations.

Document IGRT technique in planning records.

Brachytherapy exception: IMRT should not be used as a routine substitute for brachytherapy for central disease in individuals with an intact cervix; brachytherapy remains required when indicated.

NCCN guidance mandates brachytherapy for central cervical disease when indicated.

HA-WBRT coverage criteria

HA-WBRT plus memantine is supported when ALL of the following are met:

HA-WBRT eligibility: 1) Patient is planned to receive whole‑brain radiotherapy for brain metastases; 2) No metastases within the hippocampal‑avoidance region (approximately within 5 mm of the hippocampus) and no leptomeningeal disease; 3) Performance status ECOG ≤ 2 or KPS ≥ 70; 4) Estimated prognosis/life expectancy approximately ≥ 4 months; 5) Concurrent use of memantine is planned; these criteria reflect randomized phase III trial evidence demonstrating reduced cognitive failure without detriment to OS/PFS.

All listed conditions must be documented for coverage.

IMRT/advanced RT coverage criteria for head & neck cancers

Advanced/conformal RT (IMRT, VMAT, helical-IMRT) is supported for head and neck cancers when ALL of the following apply:

IMRT use in HNC: 1) Clinical indication is a head and neck cancer where sparing of critical OARs (e.g., parotid glands, pharyngeal constrictors, cochlea, optic structures, temporal lobes, larynx) is important to reduce long-term toxicity; 2) Treatment planning demonstrates expected OAR dose reduction compared with conventional techniques documented by plan comparison; 3) Technique selection (IMRT/VMAT/helical) is justified by comparative planning and multidisciplinary clinical judgment.

NCCN and RCTs support IMRT for reducing xerostomia and dysphagia without compromising tumor control.

Technique and fractionation considerations

Fractionation and dose considerations (clinical trial evidence):

Fractionation options: Randomized and prospective studies support multiple fractionation schedules (e.g., SIB‑IMRT, SEQ‑IMRT, SMART boost) for nasopharyngeal and other head and neck sites; choice of fractionation should be based on trial evidence, toxicity tradeoffs, and clinical trial availability, and novel fractionation approaches outside trials should be justified.

Some accelerated or altered fractionation schedules remain investigational and may be limited to clinical trials.

Site-specific coverage considerations

Site-specific coverage considerations and criteria logic drawn from guidelines and studies:

Brain metastases: HA‑WBRT plus memantine is recommended for individuals receiving WBRT who have no hippocampal lesions and expected survival ≥ 4 months; patients with asymptomatic brain metastases and poor KPS (≤ 50 or < 70 with systemic therapy options) may not derive benefit from RT.

ASCO/SNO/ASTRO and NCCN guidance cited.

Mediastinal lymphoma/thymic tumors: IMRT and advanced techniques may improve PTV coverage and reduce dose to heart, esophagus, spinal cord and other OARs; consider IMRT when long-term survival anticipated to minimize late toxicities, acknowledging small study sizes and heterogeneity in the literature.

Systematic reviews and single‑institution series support improved dosimetry with IMRT.

Stage III NSCLC: IMRT is preferred over 3D‑CRT in definitive chemoradiation for stage III NSCLC because of lower rates of high‑grade radiation pneumonitis with similar oncologic outcomes; heart dose metrics should guide planning.

NRG RTOG 0617 secondary analyses and NCCN statements referenced.

Covered with criteria

Evidence and guideline-aligned coverage considerations for IMRT in prostate and vulvar cancer

Prostate cancer — when IMRT is supported: IMRT is an appropriate EBRT technique for clinically localized prostate cancer across risk groups; IMRT is the current standard technique, supports dose escalation when EBRT is primary therapy, and is recommended for pelvic nodal irradiation with doses of 45–52 Gy per guideline statements.

Sources: ACR, AUA/ASTRO, NCCN.

Prostate cancer — outcomes and toxicity: Observational and randomized data indicate IMRT reduces acute and late GI/GU toxicities compared with 3D‑CRT and that moderately hypofractionated, image‑guided IMRT regimens provide acceptable long‑term tumor control with low rates of grade 3 late toxicity.

Long‑term cohort evidence supports hypofractionated schedules in appropriate patients.

Vulvar cancer — when IMRT is supported: Dose‑escalated IMRT, often with concurrent platinum‑based chemotherapy, is reported to achieve high clinical/pathologic response rates and acceptable toxicity for locally advanced vulvar cancer; IMRT with daily image verification is recommended for adjuvant or definitive pelvic treatment when SIB is used.

Revised Covered Indications (summary)

Policy revision summary regarding IMRT coverage

Revisions: Added vulvar cancer to the list of primary sites for which IMRT for Definitive Therapy is proven and medically necessary; replaced wording 'anal cancer' with 'anus/anal canal cancer'; clarified that medical records documentation may be required to assess whether the member meets clinical criteria for coverage and that benefit coverage is determined by federal, state, or contractual requirements.

Refer to the main Proven Indications list for full criteria.

IMRT used in conjunction with proton beam radiation therapy is explicitly listed as unproven and not medically necessary due to insufficient evidence of efficacy. Requests combining IMRT and proton delivery in a single treatment plan should not be approved based on current literature and policy language.

Clinical reports informing this policy frequently note limitations that reduce generalizability, including small study sizes, single-center designs, and heterogeneous prior treatments or techniques. These evidence limitations may prompt utilization review or require additional documentation to justify use of IMRT where comparative randomized data are limited.

Per guideline recommendations, IMRT should not be used as a routine substitute for brachytherapy when treating central disease in individuals with an intact cervix; brachytherapy remains the standard of care when indicated and IMRT should only be considered with explicit justification and documentation when brachytherapy is not feasible.

Hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) is not indicated when there are metastases within the hippocampal-avoidance region (approximately within 5 mm of the hippocampus) or when leptomeningeal disease is present; these findings make hippocampal sparing inappropriate according to guideline guidance.

Guidelines specify that patients with lesions involving the hippocampus are not candidates for hippocampal-avoidance WBRT. Eligibility for HA-WBRT requires absence of hippocampal metastases and documented prognosis consistent with expected cognitive benefit.

No evidence was identified supporting the combined use of IMRT and proton beam radiation therapy within a single treatment plan. The clinical literature and policy note the absence of supporting data, and combined IMRT+proton approaches should be considered unsupported.

No additional explicit exclusions are listed in the sourced document excerpts for this section.

IMRT delivered in combination with proton beam therapy is considered not medically necessary because current evidence does not demonstrate added efficacy or safety for combined delivery modalities; such combinations are listed as unproven in the policy and lack clinical trial support.

Evidence nuance: systematic reviews and trials in CNS tumors (including a Cochrane review and randomized trials) have not consistently demonstrated overall survival benefits for early versus delayed radiotherapy in low-grade gliomas; trial limitations (e.g., lack of QOL/cognitive data, risk of bias) mean timing decisions should be individualized and informed by available evidence.

Dose escalation beyond standard regimens did not improve outcomes in selected esophageal trials: a randomized comparison of 50.4 Gy versus dose escalation to 61.6 Gy showed no significant improvement in local progression-free survival or overall survival and higher serious toxicity with dose escalation, so higher-dose approaches require strong justification.

Novel fractionation schedules such as SMART boost may be feasible but lack phase III confirmation; randomized single-institution trials indicate feasibility and comparable short-term toxicity, but these approaches are discouraged outside clinical trials until larger confirmatory evidence is available.

For patients with asymptomatic brain metastases, guideline statements indicate those with poor performance status (e.g., KPS ≤ 50 or KPS < 70 who have systemic therapy options) may not derive meaningful benefit from radiotherapy; alternative systemic management or observation may be appropriate depending on clinical context.

No additional explicit exclusions are listed in the sourced document excerpts for this placeholder.

Applicable Codes and Coding Guidance

Applicable Codesmixed

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.

1–10 of 12

1/2

FDA product codes mentionedmixed

MUJ	FDA product code referenced for IMRT devices
IYE	FDA product code referenced for IMRT devices

Prior Authorization, Documentation, and Utilization Management

Prior Authorization

Coding reference and prior authorization guidance

Applicable procedure and diagnosis codes are provided for reference and do not by themselves determine coverage or payment. Prior authorization requirements should follow payer, federal, state, or contractual rules. When requesting prior authorization for IMRT/related services, include the relevant CPT/HCPCS/other codes (e.g., 77301, 77338, 77385-77387, G6015-G6017, proton delivery codes 77520-77525) and reference any related reimbursement policy guidance for code changes or replacements.

Coding list is for reference only and is not all-inclusive
Inclusion of a code does not imply coverage or guarantee payment
Refer to federal/state/contractual requirements and related reimbursement guidance

Prior Authorization

Prior authorization should document indication and planning rationale

Prior authorization requests must document the clinical indication, treatment intent, and the planning rationale demonstrating why IMRT/VMAT (or other advanced modality) is selected over non‑IMRT techniques. Where applicable, include treatment intent (definitive, postoperative, palliative), tumor site and stage, prior radiation to the same or adjacent area, and a comparison of dose distributions when a non‑IMRT technique would increase clinically meaningful dose to organs at risk (OARs).

Clinical Background and Description of Services

Background: Intensity-modulated radiation therapy (IMRT) is an advanced, high-precision external beam radiation technique that modulates beam intensity to conform dose to the three-dimensional shape of the tumor while sparing adjacent normal critical structures. IMRT is typically delivered with image guidance (IGRT) to ensure accurate target localization.

Definitions and Key Terms

inv-63: Radiation treatments for cancer with a curative intent — Definitive Therapy

DefinitionRadiation treatments for cancer with a curative intent.

ContextTerm used throughout policy to denote treatments delivered with definitive/curative intent rather than palliative intent.

Policy updateDefinition updated in the 05/01/2026 revision to reflect current terminology and supporting references.

inv-64: IMRT/VMAT recommendation — Professional society guidance that IMRT or VMAT may be preferred for OAR sparing

Professional societiesACR, ESMO, NCCN and ASTRO note IMRT/VMAT may be preferred over conventional techniques to reduce dose to normal structures and decrease acute/late toxicity.

Clinical rationale

Policy Revisions and Update Log

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for Idaho Only)

Policy CodePolicy CS064ID.B

Change TypeCriteria revisionadded indications and documentation requirements

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionProvide medical records that document the clinical indication, planning rationale, and that the member meets criteria for coverage when requesting prior authorization.

SourceLink

On This Page

Supports IMRT use to reduce normal tissue effects.

Pancreatic cancer: IMRT is associated with reduced acute and late GI toxicities compared with 3D‑CRT and is recommended by ASTRO and NCCN for localized pancreatic cancer, though evidence on OS is inconsistent.

Retrospective studies and systematic reviews summarized.

Prostate cancer: Moderately hypofractionated IMRT with daily IGRT demonstrates acceptable long‑term tumor control and low late grade 3 GI/GU toxicity over 10+ years in cohort studies; IMRT is standard EBRT technique across risk groups and recommended for pelvic nodal irradiation at guideline doses.

Large series with long follow‑up support outcomes.

Sources include NCCN and relevant series cited in the evidence base.

Document tumor site, stage, and treatment intent
Provide treatment planning rationale and plan comparison (IMRT vs non‑IMRT) when applicable
Identify OARs to be spared and expected dosimetric benefit from IMRT/VMAT

Prior Authorization

Prior authorization: guideline‑concordant indication

Prior authorization must confirm that the requested IMRT is guideline‑concordant for the indicated diagnosis and intent. For disease sites where IMRT is preferred or standard (e.g., head and neck, prostate, cervix/pelvis for definitive or postoperative treatment, esophageal cancer, mediastinal/thymic disease, select breast APBI regimens, anal/anus canal cancer, stage III NSCLC with chemoradiation), include guideline citations and how the planned technique aligns with recommendations.

Confirm guideline reference and how the plan meets recommendations
Identify selection of IMRT for pelvic definitive/postoperative treatment to minimize OAR dose
For stage III NSCLC, note IMRT is preferred over 3D‑CRT given lower high‑grade pneumonitis risk

Prior Authorization

HA‑WBRT prior authorization

For hippocampal‑avoidance whole brain radiotherapy (HA‑WBRT) requests, prior authorization must document patient eligibility: no metastases within the hippocampal‑avoidance region (typically within 5 mm of the hippocampus), absence of leptomeningeal disease, and an estimated prognosis with expected survival of at least four months. Also document planned use of memantine if applicable and the prescribed regimen (e.g., 30 Gy in 10 fractions).

Confirm no metastases within 5 mm of hippocampus and no leptomeningeal disease
Provide estimated prognosis (expected survival ≥ 4 months)
Specify memantine use and HA‑WBRT dose/fractionation (e.g., 30 Gy/10 fractions)

Prior Authorization

Prior auth: IMRT preferred for stage III NSCLC

For stage III NSCLC receiving definitive chemoradiation, prior authorization should note that IMRT is preferred over 3D‑CRT based on trial data (e.g., RTOG 0617) showing reduced high‑grade radiation pneumonitis with similar tumor control. Document how IMRT will reduce dose to heart and lungs compared with 3D techniques when applicable.

State stage III NSCLC indication and concurrent systemic therapy plan
Include dosimetric comparison or rationale showing reduced lung/heart dose versus 3D‑CRT

Prior Authorization

Prior authorization should confirm guideline‑concordant indication and technique

Prior authorization should confirm appropriate technique and guideline concordance when IMRT is requested for cancers where multiple guidelines describe IMRT as standard or recommended (e.g., prostate, vulvar, head & neck, cervix/pelvis, esophagus, mediastinal lymphoma, thymoma). Include planned IGRT methods and any adaptive or image‑guided verification strategy.

Confirm IMRT/IGRT planning consistent with guideline recommendations
Describe image‑guided verification (orthogonal imaging, CBCT, intrafraction tracking) and motion management

Documentation Required

Prior authorization/documentation may be required

Medical records documentation may be requested to support the medical necessity determination. Submission of records to prior authorization does not guarantee coverage — final determination remains subject to benefit terms and applicable laws.

Medical records may be required to assess criteria for coverage
Provision of records does not guarantee approval

Denial Risk

Documentation insufficiency

Insufficient or missing medical record documentation that fails to fully support medical necessity may result in denial or inability to complete utilization review. Provide legible, complete records including history, exam, diagnostic tests, and treatment planning materials.

Ensure records include relevant history, physical exam, imaging, pathology, prior RT dose records if applicable
Incomplete documentation may delay or result in denial

Note

Evidence limitations may prompt utilization review

Limited evidence in some disease sites or techniques (small sample sizes, single‑center reports, lack of randomized data) may prompt additional utilization review or request for supporting clinical rationale. Be prepared to supply peer‑reviewed literature or institutional data when clinical benefit is uncertain.

Provide clinical evidence or rationale for off‑list or less well‑studied indications
Acknowledgment that limited generalizability of some studies may require case‑by‑case review

Prior Authorization

IMRT not routine alternative to brachytherapy

IMRT should not be used as a routine alternative to brachytherapy for treatment of central cervical disease in patients with an intact cervix. When IMRT is proposed instead of guideline‑recommended brachytherapy, prior authorization must include a clear clinical rationale and justification referencing why brachytherapy is not feasible or appropriate for this patient.

Document reasons for deviating from brachytherapy (anatomical, medical contraindication, prior therapy)
Provide dosimetric justification if IMRT is substituted for brachytherapy

Prior Authorization

Eligibility requirements for HA‑WBRT

Eligibility criteria for HA‑WBRT must be documented: no hippocampal lesions (no metastases within 5 mm of the hippocampus), no leptomeningeal disease, and expected survival ≥ 4 months. Failure to meet these criteria generally makes the patient ineligible for HA‑WBRT.

Confirm no metastases within 5 mm of hippocampus and absence of leptomeningeal disease
Provide estimated prognosis showing expected survival ≥ 4 months

Denial Risk

Hippocampal avoidance eligibility risk

Hippocampal‑avoidance eligibility risk: patients with metastases within the hippocampal‑avoidance region or with leptomeningeal disease, or those with short expected survival, are not candidates for HA‑WBRT. Document these exclusion factors clearly in the authorization request.

If hippocampal lesions are present within 5 mm, HA‑WBRT is contraindicated
Short expected survival (< 4 months) or leptomeningeal disease excludes HA‑WBRT candidacy

Denial Risk

Combination therapy limitation

No evidence supports combining IMRT and proton beam therapy in a single treatment plan; such combined IMRT+PBT approaches are considered unproven. Prior authorization for combined modality plans should include strong clinical justification and may be subject to denial as investigational.

Combined IMRT+PBT plans lack supporting evidence and may be considered investigational
Provide justification and supporting evidence if combined approach is proposed

Documentation Required

Required medical record documentation

The patient's medical record must contain documentation that fully supports medical necessity for the requested services. Required elements include, but are not limited to: relevant medical history, physical examination findings, diagnostic imaging and reports, pathology, prior treatment records (including prior radiation doses to the same or adjacent areas), treatment intent, and detailed treatment planning notes (dose‑volume histograms, target and OAR delineation).

Include prior RT dose records and cumulative dose considerations when re‑irradiation is planned
Provide DVHs, plan comparison data, and OAR constraints used in planning

Prior Authorization

Patient selection documentation for APBI‑IMRT

For accelerated partial breast irradiation using IMRT (APBI‑IMRT), prior authorization should document patient selection consistent with the trial and guideline criteria (e.g., low recurrence‑risk features used in APBI randomized trials). Provide pathological features, tumor size, margins, nodal status, and other selection criteria used to support APBI candidacy.

Document tumor and patient features consistent with APBI trial eligibility
Include fractionation and technique details (e.g., 30 Gy/5 fractions APBI‑IMRT)

Prior Authorization

Document rationale when deviating from brachytherapy

When proposing IMRT in lieu of a guideline‑recommended brachytherapy approach (e.g., central cervical disease), prior authorization must include a documented rationale explaining why brachytherapy is not feasible or appropriate and demonstrate how IMRT will achieve comparable tumor control while minimizing OAR dose.

Provide clinical reasons (anatomical, medical contraindication, prior RT) for avoiding brachytherapy
Include dosimetric comparisons and expected impact on local control and OAR doses

Documentation Required

Required clinical documentation for HA‑WBRT

For HA‑WBRT authorization, include required clinical documentation: imaging showing absence of metastases within the hippocampal‑avoidance region, absence of leptomeningeal disease, estimated prognosis (≥ 4 months), planned memantine use if applicable, and the treatment prescription (dose/fractions) and verification approach.

Attach MRI/CT reports delineating hippocampal region and confirming no lesions within 5 mm
Specify memantine plan and radiation prescription (e.g., 30 Gy/10 fractions)

Documentation Required

Guideline‑concordant planning and IGRT documentation

Requests for IMRT should include documentation of guideline‑concordant planning and image guidance — e.g., details of IGRT approach (orthogonal imaging, CBCT, intrafraction tracking), immobilization and motion management, dose‑volume histogram constraints, and verification procedures to ensure reproducible delivery.

Describe IGRT modality and frequency, immobilization, and adaptive planning if planned
Include DVHs and planned OAR constraints consistent with guideline limits

Documentation Required

Medical records documentation requirements

Medical records must fully support the medical necessity determination. Provide legible, complete documentation and make records available on request. Failure to provide required documentation may lead to denial or inability to complete review. Benefit determination remains subject to federal, state, or contractual requirements.

Records should be legible and maintained in the patient's chart
Provision of records does not override applicable benefit or legal requirements

Note

Jurisdictional override instruction

When applying this policy, always reference federal, state, or contractual benefit requirements as they may differ from standard plan language. In the event of conflict, applicable laws and contractual terms govern coverage decisions.

Check federal/state/contractual requirements before applying policy
Applicable laws/contract terms override standard policy where conflicts exist

Note

Consider 3D‑CRT alternative when IMRT unavailable

If IMRT/VMAT is not available at the treating facility, consider a 3D‑CRT alternative when recommended by guidelines (e.g., certain CNS tumors). Prior authorization should document availability constraints and, when requesting IMRT because 3D‑CRT would be inadequate, include plan comparison demonstrating clinically meaningful OAR dose reduction.

Document that IMRT/VMAT is unavailable locally if proposing 3D‑CRT as acceptable alternative
Provide plan comparison if requesting IMRT due to inadequacy of 3D‑CRT

Step Therapy

No step therapy requirements described

There are no formal step therapy requirements described in this policy for IMRT; however, utilization management may favor advanced techniques when they demonstrably reduce OAR dose per guideline recommendations. Requests are evaluated by medical necessity rather than by step‑therapy sequencing.

No mandated step from 3D‑CRT to IMRT is specified in policy
Evaluation is based on clinical need and guideline concordance

Step Therapy

Step therapy for advanced RT

Step therapy is not established in this policy for advanced radiation techniques. While not required, when multiple modalities are clinically reasonable, provide rationale for selecting IMRT (or PBT) that demonstrates material reduction in OAR dose without compromising target coverage.

Provide comparative rationale when choosing advanced RT over conventional techniques
Emphasize OAR sparing and long‑term toxicity reduction in rationale

Step Therapy

Step approach for mediastinal/thymic RT modality

For mediastinal lymphoma and thymic RT requests, document the step approach rationale: advanced modalities (IMRT, VMAT, DIBH, IGRT, or PBT) are appropriate when necessary to spare critical OARs (heart, lungs, breasts) and to minimize mean heart dose in younger long‑term survivors. Include dosimetric comparisons to justify modality choice.

Document expected OAR benefit and potential tradeoffs (e.g., low‑dose bath)
Provide plan comparisons to 3D‑CRT or APPA when applicable

Step Therapy

Step therapy

Overall, no specific step therapy sequencing or quantity limits are mandated by this policy. Utilization management focuses on medical necessity, guideline concordance, and provision of sufficient documentation to justify the selected advanced RT modality.

Decisions rest on medical necessity and benefit plan terms
Provide full documentation to support advanced technique requests

Preferred when treating tumors near critical organs-at-risk where improved conformality and OAR sparing are clinically meaningful.

Examples of sites citedAnal carcinoma, pancreatic cancer, and other tumor sites where toxicity reduction can be achieved with IMRT/VMAT.

inv-65: IGRT / PET-based IG-IMRT — Definition of image-guided radiotherapy and PET-based integration

DefinitionIGRT: imaging at time of treatment to ensure accurate target delivery; often used with IMRT to verify position and adapt therapy.

PET-based IG-IMRTIntegration of PET imaging into IMRT planning/delivery to improve target delineation and biologic targeting; cited trial associated PET-based integration with reduced acute neutropenia in a phase II study (policy references).

Operational noteIGRT is recommended routinely with IMRT to ensure target coverage and OAR sparing per guideline statements.

inv-66: Hippocampal-avoidance whole-brain radiation therapy (HA-WBRT) — Definition and intent

DefinitionHA-WBRT: Whole-brain radiotherapy planned with IMRT techniques to avoid the hippocampal neurogenic niche in order to reduce cognitive decline when delivering WBRT.

Intended benefitAims to preserve cognitive function (learning, memory, executive function) compared with standard WBRT when used with memantine.

Eligibility criteria (guideline basis)Offered to patients receiving WBRT who have no hippocampal lesions and an expected survival of approximately ≥4 months (per ASCO/SNO/ASTRO and NCCN guidance).

inv-67: Dysphagia-optimized IMRT (DO-IMRT) — Definition of DO-IMRT planning approach

DefinitionDysphagia-optimized IMRT (DO-IMRT) is an IMRT planning approach that explicitly reduces dose to dysphagia- and aspiration-related structures (e.g., pharyngeal constrictors) to improve swallowing outcomes.

EvidencePhase 3 RCT (Nutting et al.) showed improved swallowing function (MDADI scores) at 12 and 24 months with DO-IMRT versus standard IMRT and fewer serious adverse reactions overall.

Clinical goalDesigned to reduce long-term dysphagia and related late toxicities while maintaining tumor control in oropharyngeal/hypopharyngeal cancers.

inv-68: HA-WBRT — Hippocampal avoidance WBRT definition (alternate chunk)

HA-WBRT summaryHippocampal-avoidance WBRT is a WBRT planning technique that spares the hippocampus to reduce cognitive decline and is typically combined with memantine per guideline recommendations.

Contraindication notePatients with metastases within the hippocampal-avoidance region (within ~5 mm of hippocampus) are not candidates for HA-WBRT.

FractionationWhen indicated, HA-WBRT is described in policy criteria as deliverable up to 10 fractions.

inv-69: IMRT/VMAT — IMRT and VMAT definition

IMRT definitionIntensity-modulated radiotherapy (IMRT) is an advanced conformal radiotherapy technique that modulates beam intensity to improve target coverage and spare organs at risk.

VMAT relationshipVMAT is a rotational implementation of modulated delivery (volumetric-modulated arc therapy) that achieves similar conformality and sparing benefits to IMRT.

Clinical useRecommended by guidelines for sites where OAR sparing reduces acute/late toxicity (e.g., pancreatic, head and neck, mediastinal tumors).

inv-70: IMRT / IGRT — IMRT and IGRT definition

IMRT (definition)IMRT is a conformal external beam radiation therapy technique that modulates beam intensity to shape dose to three-dimensional tumor volumes.

IGRT (definition)Image-guided radiation therapy (IGRT) uses imaging at the time of treatment (orthogonal or volumetric) to verify target position and improve accuracy of delivery.

Guideline noteGuidelines state IGRT is essential when delivering IMRT for sites such as prostate and vulvar cancer to account for motion or change and ensure appropriate coverage and OAR sparing.

inv-71: Definitive Therapy (updated definition in policy)

Updated definitionDefinitive Therapy: radiation treatments for cancer with a curative intent (policy definition updated in 05/01/2026 revision).

Usage in policyUsed to define indications where IMRT is considered proven and medically necessary when delivered with curative intent to listed primary sites.

Documentation implicationRequests for IMRT for Definitive Therapy should include documentation supporting curative intent and relevant clinical details per medical records requirements.